GlassScriptPhysician profile
Bryan F Thompson
NPI 1164424644
$10,797.88
in general payments reported to CMS, 2019-2025
35 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $268 · 2021: $207 · 2022: $2,275 · 2023: $2,123 · 2024: $2,439 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,630.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,232.47 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,433.74 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $852.72 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $847.09 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $670.39 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $500.98 | 2022-2025 | |
| Lilly USA, LLC | $472.59 | 2023-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $404.95 | 2019-2025 | Ocaliva |
| Celgene Corporation | $390.54 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $388.18 | 2019-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $332.77 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $327.65 | 2019-2025 | |
| Qol Medical, LLC | $246.39 | 2022-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $209.45 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $204.49 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $184.99 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $130.78 | 2022 | |
| Ardelyx, INC. | $129.31 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $95.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $85.45 | 2024-2025 | Pancreaze, Qsymia |
| Celltrion USA INC. | $75.29 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $75.02 | 2022-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $73.82 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $71.07 | 2023-2024 | Terlivaz |
| Shield Therapeutics INC | $61.12 | 2023 | Accrufer |
| Amgen INC. | $54.84 | 2022-2023 | Amjevita |
| Ipsen Biopharmaceuticals, INC | $54.50 | 2024-2025 | Iqirvo |
| Amag Pharmaceuticals, INC. | $50.59 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.88 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $30.36 | 2024 | Button |
| Sandoz INC. | $19.54 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2023 | Cyltezo |
| Ucb, INC. | $12.82 | 2019 | |
| Shire North American Group INC | $11.87 | 2019 | |
| Daiichi Sankyo INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.